Biotechnology

Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension

August 10, 2022 8:15 AM

Significant Milestone Achieved in Commercial Product Development Program Abbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA Pathway KELOWNA, BC / ACCESSWIRE / August 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that it has received a positive full written response from the Food and Drug Administration ("FDA") from its...

Read more

Hemogenyx Pharmaceuticals PLC Announces Appointment of Medical Director

August 10, 2022 2:00 AM

One of America's Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director LONDON, UK / ACCESSWIRE / August 10, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Koen van Besien as Medical Director. Dr van Besien is Chief of the Division of Hematology and head of the Wesley Center for...

Read more

Biolab Strengthens Its Presence With the Purchase of Exzell Pharma

August 9, 2022 12:10 PM

MARKHAM, ON / ACCESSWIRE / August 9, 2022 / Biolab Pharma announced today the acquisition of the Canadian healthcare business, Exzell Pharma, based in Markham, Ontario. The deal represents another significant step to strengthen its international presence by acquiring a sales and marketing infrastructure as well as important established brands such as Swiss Naturals, Salinex, Esoph, and Myoflex. Biolab Pharma is a subsidiary of Biolab...

Read more

Black Bird Biotech Opens Grizzly Creek Naturals CBD Affiliate Sales Sign-up Portal Ahead of Sales Program Launch

August 9, 2022 8:55 AM

FLOWER MOUND, TX / ACCESSWIRE / August 9, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced the opening of a Sign-up Portal for its Affiliate Sales Program for its Grizzly Creek NaturalsTM CBD product line. Future Grizzly Creek NaturalsTM Affiliate Sales Reps can sign up at GrizzlyCreekAffiliates.com. The Company has scheduled the program launch for September 7,...

Read more

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 4, 2022 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT Adjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23 Cinrebafusp alfa (PRS-343) demonstrating clinical benefit in HER2-expressing gastric cancer patients, but Company will cease enrollment to focus its resources First-in-human regulatory submission for PRS-220 achieved, with first subject dosing...

Read more

RepliCel Announces Material Patent Milestones in Key Markets

August 4, 2022 6:00 AM

New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as cell-based regenerative medicine products in aesthetics and orthopedics, is pleased to announce the granting...

Read more

enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022 4:45 PM

Ended the quarter with $47.2 million in cash and investments - expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / ACCESSWIRE / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the second quarter...

Read more

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

August 3, 2022 8:15 AM

TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held in New York, NY on August 8-9, 2022. The hybrid event will be held both virtually and in-person. Attendees who are interested in meeting with the company...

Read more

Apollo Endosurgery, Inc. Reports Record Global Revenue in Second Quarter 2022

August 2, 2022 4:01 PM

Grew global revenue 16% (20% in constant currency) as adoption increased across all product lines Secured FDA marketing authorization for Apollo ESGTM and Apollo REVISETM AUSTIN, TX / ACCESSWIRE / August 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2022 and recent...

Read more

Black Bird Biotech Readies for Illinois State Fair and Du Quoin State Fair in America’s Heartland and Cannabis Conference 2022 in Las Vegas

August 2, 2022 9:15 AM

FLOWER MOUND, TX / ACCESSWIRE / August 2, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that its marketing team will be exhibiting MiteXstreamTM at the Illinois State Fair in Springfield from August 11th to the 21st, the Du Quoin (Illinois) State Fair from August 26th to September 5th and Cannabis Conference 2022 in Las Vegas from August 23th to the 25th. "Exhibiting...

Read more

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

August 2, 2022 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive...

Read more

DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

August 2, 2022 6:00 AM

Independent Testing Performed by Innovacell Demonstrates the DermaPrecise™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency VANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has received test results showing that cells...

Read more

BioInvent Enrolls First Patient in Phase 1/2a Trial of BI-1607 in HER2 Positive Solid Tumors

August 1, 2022 9:15 AM

LUND, SWEDEN / ACCESSWIRE / August 1, 2022 / BioInvent International (STO:BINV) Study of BI-1607 in combination with trastuzumab in HER2 positive solid tumors First patient recruited in Spain Preclinical data indicate BI-1607 enhances the effect of trastuzumab (Herceptin®) BioInvent's fifth clinical trial; four distinct drug candidates in ongoing trials BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused...

Read more

Biovica Receives FDA Approval for DiviTum(R)TKa

July 30, 2022 7:10 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 30, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II). Biovica, active in cancer diagnostics, today announces that FDA has granted 510(k) clearance for the product DiviTum®TKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients. "We are excited to have received the formal approval from FDA for...

Read more

Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure

July 29, 2022 7:00 AM

Publication of MERIT Study Follows FDA Market Authorization of Apollo ESG™ AUSTIN, TX / ACCESSWIRE / July 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today the electronic publication of the landmark Multi-center ESG Randomized Interventional Trial (MERIT) Study in The Lancet.(1) The MERIT study is a multi-center,...

Read more

Change in the Number of Shares and Votes in BioInvent International AB

July 29, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / July 29, 2022 / BioInvent International (STO:BINV) Lund, Sweden - July 29, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per July 29, 2022 amounts to 64,967,884 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of approximately SEK 298.9 million to...

Read more

Media Alert: BrainChip Talks ML at the Edge with Jan Jongboom on Latest 'This is our Mission' Podcast

July 28, 2022 6:50 PM

LAGUNA HILLS, CA / ACCESSWIRE / July 28, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, today announced that Jan Jongboom, co-founder and CTO at Edge Impulse, is the featured guest on the latest "This is our Mission" podcast. Jongboom joins BrainChip Vice President of Worldwide Sales, Rob Telson to discuss how machine learning on neuromorphic computing can make IoT...

Read more

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

July 28, 2022 7:20 AM

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update. To...

Read more

Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company's Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.

July 28, 2022 6:30 AM

COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering its discovery and exclusive claim to conserved antigens and epitopes of the HIV virus, the PCT International Search Report concluded that inventions claimed therein are novel and inventive and thus will expectedly be issued in final international...

Read more

RepliCel’s Manufacturing Inspected by Japan’s PMDA

July 28, 2022 6:00 AM

After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences Inc. (OTCPINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative...

Read more